Synergistic effects between mTOR complex 1/2 and glycolysis inhibitors in non-small-cell lung carcinoma cells

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Jiang, Suhua ^a   Zou, Zhengzhi ^a   Nie, Peipei ^a   Wen, Ruiling ^a   Xiao, Yingying ^a   Tang, Jun ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYGLUCOSE; GLUCOSE; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PROTEIN KINASE B; RAPAMYCIN; VISTUSERTIB; CARRIER PROTEIN; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MORPHOLINE DERIVATIVE; MULTIPROTEIN COMPLEX; PROTEIN KINASE INHIBITOR; RICTOR PROTEIN, HUMAN; RPTOR PROTEIN, HUMAN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TARGET OF RAPAMYCIN KINASE; TOR COMPLEX 2;

A549 CELL LINE; APOPTOSIS; ARTICLE; CARCINOMA CELL; CARCINOMA CELL LINE; CELL METABOLISM; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; COLONY FORMING UNIT; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; ENZYME INHIBITION; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; NON SMALL CELL LUNG CANCER; PC 9 CELL LINE; RNA INTERFERENCE; SK MES 1 CELL LINE; SPECTROPHOTOMETRY; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENE SILENCING; GLYCOLYSIS; LUNG TUMOR; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR STEM CELL ASSAY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CARRIER PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DEOXYGLUCOSE; DOWN-REGULATION; GENE KNOCKDOWN TECHNIQUES; GLYCOLYSIS; HUMANS; LUNG NEOPLASMS; MORPHOLINES; MULTIPROTEIN COMPLEXES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; TUMOR STEM CELL ASSAY;

EID: 84941279825     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0132880     Document Type: Article

References (48)

1. Hsu PP, Sabatini DM Cancer cell metabolism: Warburg and beyond. 2008.
2. Cheong H, Lu C, Lindsten T, Thompson CB Therapeutic targets in cancer cell metabolism and autophagy. Nat Biotechnol. 2012; 30: 671-678. doi: 10.1038/nbt.2285 PMID: 22781696
3. Semenza GL. Tumor metabolism: cancer cells give and take lactate. J Clin Invest. 2008; 118: 3835-3837. doi: 10.1172/JCI37373 PMID: 19033652
4. WARBURG O. On the origin of cancer cells. Science. 1956; 12,3: 309-314.
5. Zhao Y, Butler EB, Tan M. Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis. 2013; 4: e532. doi: 10.1038/cddis.2013.60 PMID: 23470539
6. Birsoy K, Sabatini DM, Possemato R. Untuning the tumor metabolic machine: Targeting cancer metabolism: a bedside lesson. Nat Med. 2012; 18: 1022-1023. doi: 10.1038/nm.2870 PMID: 22772555
7. Teicher BA, Linehan WM, Helman LJ. Targeting cancer metabolism. Clin Cancer Res. 2012; 18: 5537-5545. doi: 10.1158/1078-0432.CCR-12-2587 PMID: 23071355
8. Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer. 2006; 6: 729-734. PMID: 16915295
9. Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument-Bromage H, et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell. 2002; 110: 163-175. PMID: 12150925
10. Heesom KJ, Denton RM. Dissociation of the eukaryotic initiation factor-4E/4E-BP1 complex involves phosphorylation of 4E-BP1 by an mTOR-associated kinase. FEBS Lett. 1999; 457: 489-493. PMID: 10471835
11. Shackelford DB, Vasquez DS, Corbeil J, Wu S, Leblanc M, Wu CL, et al. mTOR and HIF-1alpha-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome. Proc Natl Acad Sci USA, 2009; 106: 11137-11142. doi: 10.1073/pnas.0900465106 PMID: 19541609
12. Egan D, Kim J, Shaw RJ, Guan KL. The autophagy initiating kinase ULK1 is regulated via opposing phosphorylation by AMPK and mTOR. Autophagy. 2011; 7: 643-644. PMID: 21460621
13. Toschi A, Lee E, Xu L, Garcia A, Gadir N, Foster DA. Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin. Mol Cell Biol. 2009; 29: 1411-1420. doi: 10.1128/MCB.00782-08 PMID: 19114562
14. Toschi A, Lee E, Thompson S, Gadir N, Yellen P, Drain CM, et al. Phospholipase D-mTOR requirement for the Warburg effect in human cancer cells. Cancer Lett. 2010; 299: 72-79. doi: 10.1016/j.canlet. 2010.08.006 PMID: 20805015
15. Soliman GA. The integral role of mTOR in lipid metabolism. Cell Cycle. 2011; 10: 861-862. PMID: 21325894
16. Yecies JL, Manning BD. mTOR links oncogenic signaling to tumor cell metabolism. J Mol Med (Berl). 2011. 89: 221-228.
17. Li W, Wang J, Chen QD, Qian X, Li Q, Yin Y, et al. Insulin promotes glucose consumption via regulation of miR-99a/mTOR/PKM2 pathway. PLoS One. 2013; 8: e64924. doi: 10.1371/journal.pone.0064924 PMID: 23762265
18. Keith B, Johnson RS, Simon MC. HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer. 2012; 12: 9-22.
19. Kumar A, Harris TE, Keller SR, Choi KM, Magnuson MA, Lawrence JJ. Muscle-specific deletion of rictor impairs insulin-stimulated glucose transport and enhances Basal glycogen synthase activity. Mol Cell Biol. 2008; 28: 61-70. PMID: 17967879
20. Risson V, Mazelin L, Roceri M, Sanchez H, Moncollin V, Corneloup C, et al. Muscle inactivation of mTOR causes metabolic and dystrophin defects leading to severe myopathy. J Cell Biol. 2009; 187: 859-874. doi: 10.1083/jcb.200903131 PMID: 20008564
21. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984; 22: 27-55. PMID: 6382953
22. Lopez GJ, Gomez DR, Lin SH, Levy LB, Zhuang Y, Komaki R, et al. Risk factors for local and regional recurrence in patients with resected N0-N1 non-small-cell lung cancer, with implications for patient selection for adjuvant radiation therapy. Ann Oncol. 2013; 24: 67-74. doi: 10.1093/annonc/mds274 PMID: 23002278
23. Gridelli C, Maione P, Rossi A. The potential role of mTOR inhibitors in non-small cell lung cancer. Oncologist. 2008; 13: 139-147. doi: 10.1634/theoncologist.2007-0171 PMID: 18305058
24. Blagosklonny MV. Hypoxia, MTOR and autophagy: converging on senescence or quiescence. Autophagy. 2013; 9: 260-262. doi: 10.4161/auto.22783 PMID: 23192222
25. Crazzolara R, Bradstock KF, Bendall LJ. RAD001 (Everolimus) induces autophagy in acute lymphoblastic leukemia. Autophagy. 2009; 5: 727-728. PMID: 19363300
26. Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov. 2006; 5: 671-688. PMID: 16883305
27. Sini P, James D, Chresta C, Guichard S. Simultaneous inhibition of mTORC1 and mTORC2 by mTOR kinase inhibitor AZD8055 induces autophagy and cell death in cancer cells. Autophagy. 2010; 6: 553-554. doi: 10.4161/auto.6.4.11671 PMID: 20364113
28. Sattler UG, Hirschhaeuser F, Mueller-Klieser WF. Manipulation of glycolysis in malignant tumors: fantasy or therapy? Curr Med Chem. 2010; 17: 96-108. PMID: 19941476
29. Buller CL, Loberg RD, Fan MH, Zhu Q, Park JL, Vesely E, et al. A GSK-3/TSC2/mTOR pathway regulates glucose uptake and GLUT1 glucose transporter expression. Am J Physiol Cell Physiol. 2008; 295: C836-C843. doi: 10.1152/ajpcell.00554.2007 PMID: 18650261
30. Sun Q, Chen X, Ma J, Peng H, Wang F, Zha X, et al. Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc Natl Acad Sci USA. 2011; 108: 4129-4134. doi: 10.1073/pnas.1014769108 PMID: 21325052
31. Ramanathan A, Schreiber SL. Direct control of mitochondrial function by mTOR. Proc Natl Acad Sci USA. 2009; 106: 22229-22232. doi: 10.1073/pnas.0912074106 PMID: 20080789
32. Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol. 2004; 14: 1296-1302. PMID: 15268862
33. Masui K, Tanaka K, Akhavan D, Babic I, Gini B, Matsutani T, et al. mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc. Cell Metab. 2013; 18: 726-739. doi: 10.1016/j.cmet.2013.09.013 PMID: 24140020
34. Hagiwara A, Cornu M, Cybulski N, Polak P, Betz C, Trapani F, et al. Hepatic mTORC2 activates glycolysis and lipogenesis through Akt, glucokinase, and SREBP1c. Cell Metab. 2012; 15: 725-738. doi: 10. 1016/j.cmet.2012.03.015 PMID: 22521878
35. Esen E, Chen J, Karner CM, Okunade AL, Patterson BW, Long F. WNT-LRP5 signaling induces Warburg effect through mTORC2 activation during osteoblast differentiation. Cell Metab. 2013; 17: 745-755. doi: 10.1016/j.cmet.2013.03.017 PMID: 23623748
36. Hay N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell. 2005; 8: 179-183. PMID: 16169463
37. Wang X, Yue P, Kim YA, Fu H, Khuri FR, Sun SY. Enhancing mammalian target of rapamycin (mTOR)- targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation. Cancer Res. 2008; 68: 7409-7418. doi: 10.1158/0008-5472.CAN-08-1522 PMID: 18794129
38. Breuleux M, Klopfenstein M, Stephan C, Doughty CA, Barys L, Maira SM, et al. Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition. Mol Cancer Ther. 2009; 8: 742-753. doi: 10.1158/1535-7163.MCT-08-0668 PMID: 19372546
39. Frias MA, Thoreen CC, Jaffe JD, Schroder W, Sculley T, Carr SA, et al. mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s. Curr Biol. 2006; 16: 1865-1870. PMID: 16919458
40. Frauwirth KA, Riley JL, Harris MH, Parry RV, Rathmell JC, Plas DR, et al. The CD28 signaling pathway regulates glucose metabolism. Immunity. 2002; 16: 769-777. PMID: 12121659
41. Sommermann TG, O'Neill K, Plas DR, Cahir-McFarland E. IKKbeta and NF-kappaB transcription govern lymphoma cell survival through AKT-induced plasma membrane trafficking of GLUT1. Cancer Res. 2011; 71: 7291-7300. doi: 10.1158/0008-5472.CAN-11-1715 PMID: 21987722
42. Fernandez DMS, de Los PEE, Joaquin M, Tauler A. Activation of phosphatidylinositol 3-kinase is required for transcriptional activity of F-type 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase: assessment of the role of protein kinase B and p70 S6 kinase. Biochem J. 2000; 349: 59-65. PMID: 10861211
43. Lu CW, Lin SC, Chen KF, Lai YY, Tsai SJ. Induction of pyruvate dehydrogenase kinase-3 by hypoxiainducible factor-1 promotes metabolic switch and drug resistance. J Biol Chem. 2008; 283: 28106-28114. doi: 10.1074/jbc.M803508200 PMID: 18718909
44. Le A, Cooper CR, Gouw AM, Dinavahi R, Maitra A, Deck LM, et al. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci U S A. 2010; 107: 2037-2042. doi: 10.1073/pnas.0914433107 PMID: 20133848
45. Zou Z, Yuan Z, Zhang Q, Long Z, Chen J, Tang Z, et al. Aurora kinase A inhibition-induced autophagy triggers drug resistance in breast cancer cells. Autophagy. 2012; 8: 1798-1810. doi: 10.4161/auto. 22110 PMID: 23026799
46. Tang J, Bouyer P, Mykoniatis A, Buschmann M, Matlin KS, Matthews JB. Activated PKC{delta} and PKC{epsilon} inhibit epithelial chloride secretion response to cAMP via inducing internalization of the Na+-K+-2Cl- cotransporter NKCC1. J Biol Chem. 2010; 285: 34072-34085. doi: 10.1074/jbc.M110. 137380 PMID: 20732874
47. Liu LL, Long ZJ, Wang LX, Zheng FM, Fang ZG, Yan M, et al. Inhibition of mTOR pathway sensitizes acute myeloid leukemia cells to aurora inhibitors by suppression of glycolytic metabolism. Mol Cancer Res. 2013; 11: 1326-1336. doi: 10.1158/1541-7786.MCR-13-0172 PMID: 24008673
48. Lou YF, Zou ZZ, Chen PJ, Huang GB, Li B, Zheng DQ, et al. Combination of gefitinib and DNA methylation inhibitor decitabine exerts synergistic anti-cancer activity in colon cancer cells. PLoS One. 2014; 9: e97719. doi: 10.1371/journal.pone.0097719 PMID: 24874286